Key result
Fulminant myocarditis is a severe syndrome requiring early recognition, often necessitating mechanical circulatory support and targeted immunosuppressive therapies based on histological subtype.
Fulminant myocarditis is a life-threatening condition where prognosis and management, including mechanical circulatory support and immunosuppression, heavily depend on the histological subtype identified via endomyocardial biopsy.
Answers are grounded in this paper and cite their sources.
Supports early biopsy-guided immunosuppression in fulminant myocarditis; leaves open prospective validation of subtype-specific strategies.
Fulminant myocarditis (FM) is an uncommon syndrome characterized by sudden and severe hemodynamic compromise secondary to acute myocardial inflammation, often presenting as profound cardiogenic shock, life-threatening ventricular arrhythmias and/or electrical storm. FM may be refractory to conventional therapies and require mechanical circulatory support (MCS). The immune system has been recognized as playing a pivotal role in the pathophysiology of myocarditis, leading to an increased focus on immunosuppressive treatment strategies. Recent data have highlighted not only the fact that FM has significantly worse outcomes than non-FM, but that prognosis and management strategies of FM are heavily dependent on histological subtype, placing greater emphasis on the role of endomyocardial biopsy in diagnosis. The impact of subtype on severity and prognosis will likewise influence how aggressively the myocarditis is managed, including whether MCS is warranted. Many patients with refractory cardiogenic shock secondary to FM end up requiring MCS, with venoarterial extracorporeal membrane oxygenation demonstrating favorable survival rates, particularly when initiated prior to the development of multiorgan failure. Among the challenges facing the field are the need to more precisely identify immunopathophysiological pathways in order to develop targeted therapies, and the need to better optimize the timing and management of MCS to minimize complications and maximize outcomes.
No takes yet. Share an insight, caveat, or question.
Montero et al. (2022) conducted a review in Fulminant myocarditis. Mechanical circulatory support and immunosuppressive therapies was evaluated. Fulminant myocarditis is a severe syndrome requiring early recognition, often necessitating mechanical circulatory support and targeted immunosuppressive therapies based on histological subtype.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: